A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...

Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...

Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...

People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

A subdivision of the American Diabetes Association has begun publishing a document that aims to provide comprehensive ...

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

Shares of weight-loss drugmakers Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) spiked after the American College of Cardiology ...

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...